Terms: = Lymphoma AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716 AND Treatment
99 results:
1. [Pathogenesis and Targeted treatment Progress of Splenomegaly in Primary Myelofibrosis--Review].
Chen ZW; Wang SX; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):308-312. PubMed ID: 38387940
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy and Safety in Early application of Ruxolinitib for high-risk: Acute lymphoblastic leukemia to prevent GVHD and recurrence after allogeneic hematopoietic stem cell transplantation.
Cheng Q; Tang Y; Liu F; Li X; Fang D
Transpl Immunol; 2024 Apr; 83():101978. PubMed ID: 38302005
[TBL] [Abstract] [Full Text] [Related]
3. Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma.
Chiba M; Shimono J; Suto K; Ishio T; Endo T; Goto H; Hasegawa H; Maeda M; Teshima T; Yang Y; Nakagawa M
Blood; 2024 Apr; 143(14):1379-1390. PubMed ID: 38142436
[TBL] [Abstract] [Full Text] [Related]
4. Golidocitinib, a selective jak1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
Song Y; Malpica L; Cai Q; Zhao W; Zhou K; Wu J; Zhang H; Mehta-Shah N; Ding K; Liu Y; Li Z; Zhang L; Zheng M; Jin J; Yang H; Shuang Y; Yoon DH; Gao S; Li W; Zhai Z; Zou L; Xi Y; Koh Y; Li F; Prince M; Zhou H; Lin L; Liu H; Allen P; Roncolato F; Yang Z; Kim WS; Zhu J
Lancet Oncol; 2024 Jan; 25(1):117-125. PubMed ID: 38092009
[TBL] [Abstract] [Full Text] [Related]
5. Dependence of peripheral T-cell lymphoma on constitutively activated JAK3: Implication for JAK3 inhibition as a therapeutic approach.
Le K; Vollenweider J; Han J; Staudinger N; Stenson M; Bayraktar L; Wellik LE; Maurer MJ; McPhail ED; Witzig TE; Gupta M
Hematol Oncol; 2024 Jan; 42(1):e3233. PubMed ID: 37876297
[TBL] [Abstract] [Full Text] [Related]
6. The JAK3
Lahera A; Vela-Martín L; Fernández-Navarro P; Llamas P; López-Lorenzo JL; Cornago J; Santos J; Fernández-Piqueras J; Villa-Morales M
Mol Carcinog; 2024 Jan; 63(1):5-10. PubMed ID: 37712558
[TBL] [Abstract] [Full Text] [Related]
7. Phase I dose escalation and expansion study of golidocitinib, a highly selective jak1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas.
Song Y; Yoon DH; Yang H; Cao J; Ji D; Koh Y; Jing H; Eom H; Kwak J; Lee W; Lee J; Shin H; Jin J; Wang M; Yang Z; Kim WS; Zhu J
Ann Oncol; 2023 Nov; 34(11):1055-1063. PubMed ID: 37673210
[TBL] [Abstract] [Full Text] [Related]
8. Characteristics of Molecular Genetic Mutations and Their Correlation with Prognosis in Adolescent and Adult Patients with Acute Lymphoblastic Leukemia.
Sun X; Liu X; Li Y; Shi X; Li Y; Tan R; Jiang Y; Sui X; Ge X; Xu H; Wang X; Fang X
Oncology; 2024; 102(1):85-98. PubMed ID: 37437551
[TBL] [Abstract] [Full Text] [Related]
9. Rare lymphomas: Getting "a Bit Ahead".
Cancer Discov; 2023 Aug; 13(8):OF4. PubMed ID: 37294133
[TBL] [Abstract] [Full Text] [Related]
10. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
[TBL] [Abstract] [Full Text] [Related]
11. A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata.
Zhou C; Yang X; Yang B; Yan G; Dong X; Ding Y; Fan W; Li L; Yang D; Fang H; Ji C; Cheng H; Zhang S; Goh AH; Liu R; Gu X; Weng Z; Foley P; Sinclair R; Zhang J
J Am Acad Dermatol; 2023 Nov; 89(5):911-919. PubMed ID: 37019385
[TBL] [Abstract] [Full Text] [Related]
12. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms.
Jaeger A; Gambheer SMM; Sun X; Chernyakov D; Skorobohatko O; Mack T; Kissel S; Pfeifer D; Zeiser R; Fisch P; Andrieux G; Bräuer-Hartmann D; Bauer M; Schulze S; Follo M; Boerries M; von Bubnoff N; Miething C; Hidalgo JV; Klein C; Weber T; Wickenhauser C; Binder M; Dierks C
Blood; 2023 Jun; 141(23):2824-2840. PubMed ID: 36696631
[TBL] [Abstract] [Full Text] [Related]
13. SOHO State of the Art Updates and Next Questions | Polycythemia Vera: Is It Time to Rethink treatment?
Mora B; Passamonti F
Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):79-85. PubMed ID: 36566109
[TBL] [Abstract] [Full Text] [Related]
14. JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.
Stein BL
Leuk Lymphoma; 2023 Feb; 64(2):292-299. PubMed ID: 36301740
[TBL] [Abstract] [Full Text] [Related]
15. IL-7: Comprehensive review.
Winer H; Rodrigues GOL; Hixon JA; Aiello FB; Hsu TC; Wachter BT; Li W; Durum SK
Cytokine; 2022 Dec; 160():156049. PubMed ID: 36201890
[TBL] [Abstract] [Full Text] [Related]
16. Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma.
Gluud M; Pallesen EMH; Buus TB; Gjerdrum LMR; Lindahl LM; Kamstrup MR; Bzorek M; Danielsen M; Bech R; Monteiro MN; Blümel E; Willerslev-Olsen A; Lykkebo-Valløe A; Vadivel CK; Krejsgaard T; Bonefeld CM; Geisler C; Becker JC; Koralov SB; Iversen L; Litman T; Woetmann A; Ødum N
Blood; 2023 Jan; 141(2):180-193. PubMed ID: 36122387
[TBL] [Abstract] [Full Text] [Related]
17. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
Roskoski R
Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
[TBL] [Abstract] [Full Text] [Related]
18. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours.
Larson RC; Kann MC; Bailey SR; Haradhvala NJ; Llopis PM; Bouffard AA; Scarfó I; Leick MB; Grauwet K; Berger TR; Stewart K; Anekal PV; Jan M; Joung J; Schmidts A; Ouspenskaia T; Law T; Regev A; Getz G; Maus MV
Nature; 2022 Apr; 604(7906):563-570. PubMed ID: 35418687
[TBL] [Abstract] [Full Text] [Related]
19. A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.
Zeidan AM; Cook RJ; Bordoni R; Berenson JR; Edenfield WJ; Mohan S; Zhou G; Asatiani E; Srinivas N; Savona MR
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):523-534. PubMed ID: 35260349
[TBL] [Abstract] [Full Text] [Related]
20. Transient Inhibition of the JAK/STAT Pathway Prevents B-ALL Development in Genetically Predisposed Mice.
Casado-García A; Isidro-Hernández M; Oak N; Mayado A; Mann-Ran C; Raboso-Gallego J; Alemán-Arteaga S; Buhles A; Sterker D; Sánchez EG; Martínez-Cano J; Blanco O; Orfao A; Alonso-López D; De Las Rivas J; Riesco S; Prieto-Matos P; González-Murillo Á; García Criado FJ; García Cenador MB; Radimerski T; Ramírez-Orellana M; Cobaleda C; Yang JJ; Vicente-Dueñas C; Weiss A; Nichols KE; Sánchez-García I
Cancer Res; 2022 Mar; 82(6):1098-1109. PubMed ID: 35131871
[TBL] [Abstract] [Full Text] [Related]
[Next]
